# Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

> **NCT00897806** · — · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Ovarian Cancer
- Peritoneal Cavity Cancer

## Interventions

- **GENETIC:** Microarray analysis
- **OTHER:** Laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00897806
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2002-02
- **Primary completion:** 2006-02
- **Final completion:** 2009-02
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Terminated due to slow accrual.
- **Last updated:** 2012-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00897806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00897806, "Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00897806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*